The Koch Clinical Investigator (KCI) program is a key element of the interdisciplinary design of the Koch Institute. Koch Clinical Investigators work side by side with MIT scientists and engineers to invent new solutions to the problems of cancer..
Dr. Alice T. Shaw Charles W. (1955) and Jennifer C. Johnson Koch Institute Clinical Investigator
The KCI program provides "top of their class" physician-scientists a unique opportunity to participate in cutting-edge cancer research while maintaining clinical activity at Boston-area oncology treatment centers. The investigators' dual role ensures that they remain involved in clinical practice, which in turn benefits KI researchers by providing a front-line view of clinical challenges in cancer treatment.
Eligible andidates for the KCI program are sub-specialty board-certified licensed by the Massachusetts Board of Medical Examiners; are at the postdoctoral, instructor, or assistant-professor level; and have a record of productivity in clinical, translational, and basic research.
The selected individuals receive dedicated lab space and research support, and work closely with faculty mentors at the Koch Institute. They spend between 10 and 50 percent of their time treating patients.
The first Koch Clinical Investigators began their appointments in 2009. Each three- to five- year appointment requires annual funding of $250,000, which covers personnel, equipment, and research costs. The KCI occupy dedicated space in the Koch Institute's newly built, state-of-the-art research and technology facility. At full capacity, the KCI program will include up to seven investigators.